Sinopharm Group Co. Ltd (X2S) — Cash Flow Quality Index
Sinopharm Group Co. Ltd (X2S) has a Cash Flow Quality Index of -1.05x as of June 2023. Operating cash flow of €-2.63 Billion is below net income of €2.51 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore X2S operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sinopharm Group Co. Ltd Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Sinopharm Group Co. Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see X2S operating cash flow.
Annual Cash Flow Quality Index for Sinopharm Group Co. Ltd (2013–2025)
Year-by-year earnings quality comparison for Sinopharm Group Co. Ltd.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.98x | €14.14 Billion | €7.16 Billion | ▲ +20.6% |
| 2024 | 1.64x | €11.55 Billion | €7.05 Billion | ▼ -13.7% |
| 2023 | 1.90x | €17.17 Billion | €9.05 Billion | ▼ -22.9% |
| 2022 | 2.46x | €20.96 Billion | €8.53 Billion | ▲ +105.0% |
| 2021 | 1.20x | €9.31 Billion | €7.76 Billion | ▼ -22.7% |
| 2020 | 1.55x | €11.15 Billion | €7.19 Billion | ▼ -48.3% |
| 2019 | 3.00x | €18.78 Billion | €6.25 Billion | ▲ +379.7% |
| 2018 | 0.63x | €3.65 Billion | €5.84 Billion | ▲ +8.8% |
| 2017 | 0.58x | €3.21 Billion | €5.58 Billion | ▼ -71.1% |
| 2016 | 1.99x | €9.26 Billion | €4.65 Billion | ▼ -44.0% |
| 2015 | 3.56x | €13.41 Billion | €3.77 Billion | ▲ +83.8% |
| 2014 | 1.93x | €5.56 Billion | €2.87 Billion | ▼ -11.9% |
| 2013 | 2.20x | €4.94 Billion | €2.25 Billion | — |